CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 216 enrolled
Drug / intervention
Savolitinib + Osimertinib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05015608
NCT05015608Phase 3Completed
CompareCT.gov

Clinical Study to Evaluate the Efficacy, Safety and Tolerability of Savolitinib + Osimertinib Versus Pemetrexed + Platinum in Treatment of Patients With NSCLC With MET Amplification

Hutchison Medipharma Limited·interventional·Posted Aug 20, 2021·Updated May 27, 2026

In Brief

A Phase 3 clinical trial evaluating Savolitinib + Osimertinib and Pemetrexed + Cisplatin /Carboplatin for Non-small Cell Lung Cancer. Completed, enrolled 216 participants across 1 site.

Detailed Summary

This study will look at how effective the study drug(Savolitinib combined with Osimertinib) versus Pemetrexed combined with platinum in treatment of patients with locally advanced or metastatic NSCLC with MET amplification after failure of the first-line EGFR inhibitor therapy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-small Cell Lung Cancer
CountriesChina
Collaborators--

Timeline

Phase 3CompletedFinished
20222023202420252026
First PostedAug 20, 2021
Enrollment StartNov 22, 2021
Primary CompletionAug 22, 2025
TodayJul 1, 2026
Enrollment to primary: 3.8 yearsPosted 4.9 years ago

Interventions

Savolitinib + Osimertinibdrug

Subjects will receive Savolitinib orally once per day (QD) + Osimertinib orally QD,21day cycles (every 3 weeks) until disease progression, death, adverse event (AE) leading to discontinuation or withdrawal of consent.

Pemetrexed + Cisplatin /Carboplatindrug

Pemetrexed combined with platinumon on Day 1 of 21day cycles (every 3 weeks)